Antifungal stewardship in a tertiary-care institution: A bedside intervention

Clinical Microbiology and Infection

Volumn 21, Issue 5, 2015, Pages 492.e1-492.e9

  Valerio, M ^a,b,d   Munoz P ^a,b,c,d   Rodriguez C G ^a,b,d   Caliz, B ^a   Padilla, B ^a,d   Fernandez Cruz A ^a,d   Sanchez Somolinos M ^a,d   Gijon P ^a,d   Peral, J ^a,d   Gayoso, J ^a,d   Frias, I ^a,d   Salcedo, M ^a,d   Sanjurjo, M ^a,b,d   Bouza, E ^a,b,c,d   Bustinza, A ^d   Caliz B ^d   Escribano, P ^d   Fernandez Quero J ^d   Guinea, J ^d   Kestler, M ^d   de Lorenzo, A ^d   Martinez M C ^d   Menarguez M C ^d   Navarro, M ^d   Pelaez T ^d   Rincon D ^d   Sanchez C ^d   Serrano, D ^d   Vena, A ^d   Verde, E ^d   Zamora, E ^d   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

^d NONE

Author keywords

Antifungals; Candidaemia; Cost savings; Invasive aspergillosis; Stewardship

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL STEWARDSHIP PROGRAM; ARTICLE; CANDIDEMIA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MORTALITY; NEPHROTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PURCHASING; TERTIARY HEALTH CARE; TIME SERIES ANALYSIS; ADOLESCENT; AGED; CHILD; COST; DRUG UTILIZATION; ECONOMICS; INFANT; MIDDLE AGED; MYCOSES; NEWBORN; POLICY; PRESCHOOL CHILD; STANDARDS; SURVIVAL ANALYSIS; TERTIARY CARE CENTER; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYCOSES; ORGANIZATIONAL POLICY; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930532813     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.01.013     Document Type: Article

References (25)

1. Ananda-Rajah M.R., Slavin M.A., Thursky K.T. The case for antifungal stewardship. Curr Opin Infect Dis 2012, 25:107-115.
2. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
3. Apisarnthanarak A., Yatrasert A., Mundy L.M. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010, 31:722-727.
4. Swoboda S., Lichtenstern C., Ober M.C., Taylor L.A., Storzinger D., Michel A., et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009, 55:418-424.
5. Standiford H.C., Chan S., Tripoli M., Weekes E., Forrest G.N. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012, 33:338-345.
6. López-Medrano F., San Juan R., Lizasoain M., Catalán M., Ferrari J.M., Chaves F., et al. Anon-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013, 19:56-61.
7. Mondain V., Lieutier F., Hasseine L., Gari-Toussaint M., Poiree M., Lions C., et al. A6-year antifungal stewardship programme in a teaching hospital. Infection 2013, 41:621-628.
8. Guarascio A.J., Slain D., McKnight R., Petros K., Parker J., Wilson A., et al. Amatched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2013, 35:145-148.
9. Stone S.P., Cooper B.S., Kibbler C.C., Cookson B.D., Roberts J.A., Medley G.F., et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. JAntimicrob Chemother 2007, 59:833-840.
10. Hoffmann T.C., Glasziou P.P., Boutron I., Milne R., Perera R., Moher D., et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014, 348:g1687.
11. Valerio M., Munoz P., Rodriguez-Gonzalez C., Sanjurjo M., Guinea J., Bouza E. Training should be the first step toward an antifungal stewardship program. Enferm Infec Microbiol Clin 2014 Jul 24, pii: S0213-005X(14)00205-5. http://dx.doi.org/10.1016/j.eimc.2014.04.016 [Epub ahead of print].
12. Valerio M., Rodriguez-Gonzalez C.G., Munoz P., Caliz B., Sanjurjo M., Bouza E. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. JAntimicrob Chemother 2014, 69:1993-1999.
13. Leon C., Ruiz-Santana S., Saavedra P., Almirante B., Nolla-Salas J., Alvarez-Lerma F., et al. Abedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
14. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
15. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
16. Maertens J., Marchetti O., Herbrecht R., Cornely O.A., Fluckiger U., Frere P., et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transpl 2011, 46:709-718.
17. Azoulay E., Dupont H., Tabah A., Lortholary O., Stahl J.P., Francais A., et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012, 40:813-822.
18. Nivoix Y., Launoy A., Lutun P., Moulin J.C., Phai Pang K.A., Fornecker L.M., et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. JAntimicrob Chemother 2012, 67:2506-2513.
19. Pavese P., Ouachi Z., Vittoz J.P., Lebeau B., Foroni L., Allenet B., et al. Adequacy of new systemic antifungal agents prescriptions in a teaching hospital. Med Malad Infect 2007, 37(Suppl.3):S223-S228.
20. Bassetti M., Molinari M.P., Mussap M., Viscoli C., Righi E. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 2013, 19:E281-E284.
21. Aguilar-Guisado M., Martin-Pena A., Espigado I., Ruiz Perez de Pipaon M., Falantes J., de la Cruz F., et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012, 97:464-471.
22. Barnes R.A. Directed therapy for fungal infections: focus on aspergillosis. JAntimicrob Chemother 2013, 68:2431-2434.
23. Antworth A., Collins C.D., Kunapuli A., Klein K., Carver P., Gandhi T., et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacotherapy 2013, 33:137-143.
24. Raymond S., Henon T., Grenouillet F., Legrand F., Woronoff-Lemsi M.C., Hoen B., et al. Clinical audit on the use of expensive systemic antifungals in the Besancon University Hospital. Med Malad Infect 2009, 39:125-132.
25. Cook P.P., Catrou P.G., Christie J.D., Young P.D., Polk R.E. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. JAntimicrob Chemother 2004, 53:853-859.